Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study
INTRODUCTION: The phase 3 REVISIT trial evaluated aztreonam-avibactam versus meropenem ± colistin for complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). This descriptive post hoc analysis explored efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP. METHODS: This post hoc analysis included patients who received colistin plus meropenem (all with baseline Acute Physiology and Chronic Health Evaluation II [APACHE II] scores ≥ 8) and patients who received aztreonam-avibactam with baseline APACHE II scores ≥ 8, for comparable baseline severity. The primary efficacy endpoint was adjudicated clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) and clinically evaluable (CE) analysis sets. Secondary endpoints included clinical cure rate at TOC by infection type, favorable microbiological response at TOC, 28-day mortality, and safety. Efficacy and safety outcomes were compared descriptively. RESULTS: Overall, we included 186 patients in the ITT population (aztreonam-avibactam, n = 160; colistin plus meropenem, n = 26). Clinical cure rates (95% CI) were 63.1% (55.5-70.3) and 53.8% (35.1-71.8) for aztreonam-avibactam and colistin plus meropenem, respectively (ITT). Results were similar in the CE analysis set. Clinical cure rates in both cIAI and HAP/VAP subgroups were consistent with the overall results, although 95% CIs were wide and the number of patients treated with colistin plus meropenem was small. Microbiological response rate was 71.7% for aztreonam-avibactam and 46.7% for colistin plus meropenem (microbiological ITT). Twenty-eight-day mortality was similar for aztreonam-avibactam (7.5%) and colistin plus meropenem (11.5%; ITT). Proportions of patients with all-cause adverse events (AEs) and serious AEs were generally similar in both groups, with fewer treatment-related AEs for aztreonam-avibactam. CONCLUSIONS: This exploratory post hoc analysis provides further insights into the efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP who were critically ill. CLINICAL TRIAL REGISTRATION: NCT number: NCT03329092.
Authors
- Naglaa Mohamed (ORCID: https://orcid.org/0000-0002-0573-1721)
- José Miguel Cisneros (ORCID: https://orcid.org/0000-0001-5001-672X)
- Yongjie Zhao (ORCID: https://orcid.org/0009-0006-4162-0136)
- 许进福
- Heidi K. Leister-Tebbe
- Yehuda Carmeli (ORCID: https://orcid.org/0009-0001-9248-2187)
- Minggui Wang (ORCID: https://orcid.org/0000-0001-7682-5859)
- George L. Daikos (ORCID: https://orcid.org/0000-0001-5365-4874)
- Joanne Louise Leaney
- Jinyi Yuan (ORCID: https://orcid.org/0000-0002-1108-3994)
- Shweta Kamat (ORCID: https://orcid.org/0000-0003-3584-5014)
- Michele Wible
- Mical Paul (ORCID: https://orcid.org/0000-0003-2317-1112)
- Wenjuan Xu
- Ying Ma
Institutions
- Technion – Israel Institute of Technology (IL)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- National and Kapodistrian University of Athens (GR)
- Fudan University (CN)
- Tel Aviv Sourasky Medical Center (IL)
- Rambam Health Care Campus (IL)
- Shanghai Pulmonary Hospital (CN)
- Instituto de Biomedicina de Sevilla (ES)
- Pfizer (China) (CN)
- Hospital Universitario Virgen del Rocío (ES)
- Huashan Hospital (CN)
- Pfizer (India) (IN)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1007/s40121-026-01477-3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Pfizer
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Biomedical Advanced Research and Development Authority